Pharmaqo GW50516 (CARDARINE) 20mg x 60
£49.99
Description
Classification
Pharmaqo GW501516 20mg x 60, commonly referred to as Cardarine, is marketed as containing GW501516, an experimental compound associated with the PPARδ (peroxisome proliferator-activated receptor delta) pathway. It is not a SARM or anabolic steroid. GW501516 remains an investigational compound and is not an authorised UK medicine for weight loss, endurance enhancement, bodybuilding or athletic performance.
What is Pharmaqo GW501516 (Cardarine) 20mg x 60?
GW501516 was developed as a research compound designed to activate PPARδ, a nuclear receptor involved in lipid and energy metabolism. It attracted scientific interest because of its effects on metabolic pathways involved in fatty-acid utilisation and energy regulation.
Pharmaqo GW501516 20mg x 60 is marketed as containing 60 units with a stated strength of 20mg each. Products obtained outside regulated pharmaceutical supply chains may have uncertain identity, purity, concentration and manufacturing quality. Packaging claims alone cannot independently verify the contents.
Dosage
There is no approved UK dosage regimen for GW501516 for weight management, bodybuilding, endurance or athletic performance. Research findings should not be converted into instructions for personal use.
Because GW501516 is an investigational compound with important safety concerns, particularly regarding long-term exposure, self-administration is not recommended. Anyone who has used or is considering using Cardarine should discuss potential risks with a qualified healthcare professional.
How Does Pharmaqo GW501516 (Cardarine) 20mg x 60 Work?
GW501516 primarily acts as an agonist of PPARδ, a nuclear receptor involved in regulating genes associated with fatty-acid metabolism and energy utilisation.
Activation of PPARδ can influence how cells handle fatty acids and energy substrates. This mechanism explains why the compound has attracted research interest in metabolic and exercise-related studies. However, biological activity does not establish that Cardarine provides a safe or clinically appropriate performance benefit.
Benefits
Research involving GW501516 has investigated metabolic and exercise-related effects, which has contributed to its popularity in online fitness communities. However, these experimental findings should not be presented as proven benefits for recreational users.
Areas of research interest include:
- Investigation of fatty-acid metabolism.
- Study of energy utilisation.
- Research into PPARδ signalling.
- Investigation of metabolic regulation.
- Experimental research into exercise-related pathways.
Importantly, GW501516 has not been established as a safe performance-enhancing treatment, and its potential risks need to be considered carefully.
When Should You Take Pharmaqo GW501516 (Cardarine) 20mg x 60?
There is no medically approved UK schedule for taking GW501516 for bodybuilding, endurance or weight loss. Online dosing schedules and performance-enhancement cycles should therefore not be treated as clinically validated recommendations.
Anyone who has already taken Cardarine and develops unusual or persistent symptoms should seek appropriate medical advice rather than attempting to manage potential adverse effects independently.
When Should You Not Take Pharmaqo GW501516 (Cardarine) 20mg x 60?
GW501516 should not be regarded as an ordinary nutritional supplement. Particular caution is appropriate because its long-term safety profile has not been established.
Professional medical advice is especially important for individuals who:
- Have liver or metabolic disorders.
- Have unexplained changes in liver-function tests.
- Have a history of cancer or are undergoing cancer treatment.
- Are pregnant or breastfeeding.
- Are under 18.
- Take medicines affecting metabolic or liver function.
- Have an unexplained medical condition requiring investigation.
What is the Mechanism of Pharmaqo GW501516 (Cardarine) 20mg x 60?
GW501516 activates PPARδ, a receptor involved in regulating gene expression. PPARδ signalling influences lipid metabolism, fatty-acid oxidation and energy-related processes in various tissues.
This mechanism is different from that of anabolic steroids, which primarily activate androgen receptors. Understanding this distinction is important because Cardarine should not be described as a testosterone-based anabolic compound or a conventional SARM.
Uses of Pharmaqo GW501516 (Cardarine) 20mg x 60
GW501516 has primarily been investigated as an experimental research compound. Scientific studies have examined its potential effects on lipid metabolism, energy utilisation and PPARδ-mediated biological pathways.
Online fitness communities may promote Cardarine for endurance, fat loss or exercise performance. These are not authorised UK medical uses, and experimental research should not be interpreted as evidence that recreational use is safe.
Warnings and Precautions for Pharmaqo GW501516 (Cardarine) 20mg x 60
One of the most important considerations surrounding GW501516 is its uncertain long-term safety. Development of the compound was discontinued after safety concerns emerged during research, including findings involving tumours in animal studies.
Important considerations include:
- Long-term human safety has not been established.
- Animal studies raised significant cancer-related concerns.
- It is not an authorised UK medicine.
- Products from unregulated sources may contain inaccurate ingredients or concentrations.
- Potential interactions with other substances cannot be reliably predicted.
- Liver or metabolic abnormalities should be medically assessed.
The absence of an immediate side effect should not be interpreted as evidence of long-term safety.
Side Effects of Pharmaqo GW501516 (Cardarine) 20mg x 60
Because GW501516 is an investigational compound, its complete human safety profile has not been established. Reported or suspected concerns should therefore be taken seriously rather than assuming the compound is safe because it does not produce conventional steroid effects.
Potential concerns may include:
- Changes in metabolic markers.
- Possible effects on liver function.
- Unknown long-term effects on cellular growth.
- Potential interactions with other medicines or compounds.
- Uncertainty regarding cancer-related risk.
Anyone experiencing persistent or unusual symptoms after using an investigational compound should seek medical advice.
Storage for Pharmaqo GW501516 (Cardarine) 20mg x 60
Storage requirements depend on the specific formulation and manufacturer’s instructions. Any legitimate research preparation should be stored according to its accompanying guidance.
Keep the product securely away from children and pets and protect it from excessive heat, moisture and direct sunlight. Do not use tablets or capsules that appear damaged, contaminated or substantially different from their original condition.
Where to Buy Pharmaqo GW501516 (Cardarine) 20mg x 60?
To get Pharmaqo GW50516 (CARDARINE) 20mg x 60 online, go to Steroid Sanctuary today to get the best deal on this medicine.
Frequently Asked Questions
1. What is GW501516?
GW501516, commonly called Cardarine, is an experimental compound that activates PPARδ and has been studied for its effects on lipid and energy metabolism.
2. Is Cardarine a SARM?
No. Cardarine is not a SARM or anabolic steroid. It is a PPARδ agonist with a different mechanism of action.
3. Is GW501516 approved in the UK?
No. It is not an authorised UK medicine for weight loss, bodybuilding, endurance or athletic performance.
4. Why are there safety concerns about Cardarine?
Animal research raised significant concerns involving tumour development, and the compound’s long-term safety in humans has not been established.
5. What should I do if I have used Cardarine and feel unwell?
Seek advice from a qualified healthcare professional and explain what substance you have taken. Persistent or serious symptoms should be medically assessed rather than managed through online advice.
